Two-year outcome of the paclitaxel-eluting Legflow balloon catheter in the treatment of long and complex femoropopliteal lesions
Longer term follow-up confirms there is no safety-concern on this paclitaxel device. The excellent results of the newer drug-eluting devices, and the Legflow paclitaxel-eluting balloon in particular, is a valid and effective alternative to treat long and complex "real-world" femoropopliteal lesions.
Authors
- Dierk Scheinert (ORCID: https://orcid.org/0000-0001-6859-9679)
- Giovanni Torsello
- Marc Bosiers (ORCID: https://orcid.org/0000-0002-4554-6467)
- Koen Deloose (ORCID: https://orcid.org/0000-0001-5434-7323)
- Michel Bosiers (ORCID: https://orcid.org/0009-0001-9419-8163)
- Jeroen Hendriks (ORCID: https://orcid.org/0000-0003-4326-9256)
- Roel Beelen
- Jürgen Verbist (ORCID: https://orcid.org/0000-0001-5830-4515)
- Joren Callaert
- Lieven Maene
- Koen Keirse
- Wouter Van den Eynde
Institutions
- Onze Lieve Vrouwziekenhuis Hospital (BE)
- Antwerp University Hospital (BE)
- University Hospital Leipzig (DE)
- Imelda Hospital (BE)
- St. Franziskus Hospital (DE)
- AZ Sint-Blasius (BE)
Publication Details
- Journal
- The Journal of Cardiovascular Surgery
- Published
- 2024-12-10
- DOI
- https://doi.org/10.23736/s0021-9509.24.12920-5
- Citations
- 2
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 1.15